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Demand for novel chemotherapeutic agents that treat Human African 
Trypanosomaiasis (HAT) persists. A series of compounds sharing a 3,4’diphephyl 
ether skeleton were prepared for a structure activity relationship (SAR) study 
evaluating antitrypansomal drug candidates. Trypanocidal assays performed in vitro
by the Swiss Tropical and Public Health Institute identified a lead with an IC50 of 1.35 
μg/mL analogous to a compound previously made in our laboratory. A slight 
improvement in activity (10%) was observed when changing the molecular 
substitution pattern from 4,4’ to 3,3’; however, the result is equivocal. Furthermore, in 
vitro test results demonstrated the weakness of amides as side chain functional 
groups, emphasizing the role of cationic moieties. The methods developed and 
material produced from this research enables the rapid production of new 
compounds to further investigate these observations.                  
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Human African Trypanosomiasis (HAT) is a debilitating tropical disease caused by 
the flagellar parasitic protozoa Trypanosoma Brucei. Left untreated, trypanosoma
parasites invade a patient’s brain and induce neurological changes such as sleep 
disorder, ataxia, psychosis, coma, and ultimately death. Fortunately, aggressive 
epidemiological intervention by the World Health Organization has limited the spread 
of the disease in recent years. However, approximately 70 million people distributed 
over a surface of 1.55 million km2 are estimated to be at differing levels of risk of 
contracting HAT. While current drug treatments— suramine, pentamidine, nifurtumox, 
and melarsoprol— are effective, they are also costly, inconvenient, and toxic. 
Therefore, there is ongoing demand for novel chemotherapeutic agents that destroy 
the parasite. Nonetheless, since HAT affects primarily impoverished populations, 
pharmaceutical firms are disinterested in pursuing new HAT drug compounds. 
Therefore, academic research is critical to HAT drug discovery. 
Contemporary drug design attempts to exploit known biochemical 
pathways associated with disease. The best therapeutic compounds, potent with 
limited side effects, often modulate a specific and well understood process. Sadly, the 
mechanism of action of current HAT treatments is poorly understood. Hence, HAT 
drug development relies on modifying the chemical structure of compounds with 
known efficacy. Systematically changing molecular shape, size, rigidity, or functional 
groups can identify patterns that correlate chemical structure to biological activity. 
Such experiments are called structure activity relationship (SAR) studies. 
Internationally, the activity of anti-trypanosomal drugs is assayed by the 
Swiss Tropical and Public Health Institute in Basel, Switzerland. They report the drug 
concentration necessary to inhibit half of a parasite load, in vitro IC50 values, 
measured in triplicate and referenced to melarsoprol (IC50 = 1 ng/mL) . A common 
worldwide assay ensures that compared data is meaningful. Promising preliminary 
compounds begin with low microgram per milliliter IC50 activities; whereas, strong 
drug candidates require nanogram per milliliter IC50 activities.
The diversity of promising HAT drug candidates exhibiting ng/mL IC50 is 
staggering. Many families of compounds have worked, so it’s sufficient to merely pick 
one. This work is based on the lead compound G71ML (IC50 = 0.68 μg/mL), a para-
substituted diphenyl ether amino acid previously prepared in our laboratory. 
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Scheme 1. Synthesis of Starting Materials Scheme 2. Derivatization of 1
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General Methods
(a) Nucleophilic Aromatic Substitution: K2CO3 (2 eq.), anhy. DMF, air free, 130 °C, 24 hr
(b) Cu(II) Bromide Oxidation: 70% TBuOOH (4 eq.), Cu(II)Br2 (0.1 eq.) acetonitrile, 23 °C, 1 hr. 
(c) Sodium Borohydride Reduction: NaBH4 (3 eq.), methanol, 23°C, 1hr  
(d) Caddick Reduction: NaBH4 (8 eq.), NiCl2∙2 H20 (0.2 eq.), Boc2O (2 eq.), 0 °C, 15 hr. 
(e) Oxidative Amination: 30% H2O2 (1 eq.), K2CO3 (0.5 eq.), DMSO, 0 °C to 23°C, 1 hr
(f) Acidic Precipitation: Anhydrous HCl in ethyl acetate, 23°C, 5 min.  
Scheme 3. Derivatization of 3 and 4
3,4’-substituted diphenyl ether starting materials were synthesized from fluoro
or hydroxy substituted benzonitriles and benzaldydes using base-catalyzed 
nucleophilic aromatic substitution. Then, general oxidative, amidative, and 
reductive methods derivatized these precursors to testable products. The 
chemical characterization of each included: melting point, nuclear magnetic 
resonance spectroscopy, infrared spectroscopy, and elemental analysis.     
Of the sixteen compounds prepared, four were sent to the Swiss TPHI for 
trypanosomal assay: 13 (3-OH,4’-ONH2), 15 (3-OH,4’-CH2NH3+), 31 (3-OH,4’-
OH), and 41 (3-ONH2,4’-ONH2). The results are summarized in Table 1. 
Conclusion and Future Work     
The 3,4’ alcohol amine,15, exhibited the highest trypanocidal activity of the 
compounds tested. This was expected since it’s chemical functionality is 
analogous to known compounds made in our laboratory, G71ML and AM272.     
Figure 1. Comparison of Diphenyl Ether Derivatives 
The prepared derivatives have a 3,4’ substitution pattern 
whereas our previous work focused on 4,4’ substituted compounds. The 
enhanced activity of 15 relative to AM272 suggests that 3,4’ substituted 
compounds may be superior in general. However, at present, the claim is 
equivocal.
Another important finding is the apparent unsuitability of amides 
as side chain functional groups. The amide analog of 15, 13, is an order of 
magnitude less active. This emphasizes that cationic groups, such as the 
protonated amine, are important structural features of active HAT drugs.
The preliminary findings of the SAR study support the notion of 3,4’ 
substitution patterns in HAT drugs. Diphenyl ether amide derivatives, 
however, make poor drug compounds. 
Future work will complete the synthesis and assay of the 
best remaining candidates of the group (3-CH2NH3+, 4’-OH; 3-CH2NH3+, 4’-
CH2NH3+). Subsequently, the starting materials made during the project 
will be applied to the rapid synthesis of other promising 3,4’ analogs.
(1) Khan, O. Drug Targets Insights. 2007, 2, 129-146.
(2) Simarro, P. P.; Cecchi, G.; Franco, J. R.; Paone, M.; Diarra, A.; Ruiz-Postigo, J.
A.; Fevre, E. M.; Mattioli, R. C.; Jannin, J. G. PLOS Neglected Tropical 
Diseases 2012, 10, 1-12.
(3) Montalvo-Quiros, S. Taladriz-Sender, A. Kaiser, M. Dardonville, C. J. Med. 
Chem. 2015, 58, 1940-1949.
(4) Caddick, S. Judd, D. B. de K. Lewis, A. K, Reich, M.T. Williams, M.R.V.
Tetrahedron 2003, 59, 5417-5423. 
(5) Prinz, H. et. al. J. Med. Chem. 2011, 54, 4227-4263. 
(6) Zhao, H. Vandenbossche, C. P. Koenig, S.G. Singh, S. P. Bakale, R. P.
Organic Letters. 2008 3, 505 -507.
(7) Travis, B.R. Sivakumar, M, Hollist, G.O. Borhan, B. Org. Lett. 2003, 7, 1031
-1034. 
(8) Uyanik, M. Akakura, M. Ishihara, K. J. Am. Chem. Soc. 2009, 131, 251-262. 
(9) Das, R; Chakraborty, D. Applied Organometallic Chemistry. 2011, 25, 437-442.
